Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus

Phase 2

Conditions: Esophageal Cancer
Gastric Cancer

First Posted Date: 2004-08-10

Last Posted Date: 2013-12-19

Lead Sponsor: Robert H. Lurie Cancer Center

Registration Number: NCT00005607

Locations: 🇺🇸
Vanderbilt Cancer Center, Nashville, Tennessee, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 1 locations

Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: Irinotecan

First Posted Date: 2004-08-10

Last Posted Date: 2012-09-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 10

Registration Number: NCT00005626

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: cetuximab
Drug: irinotecan hydrochloride

First Posted Date: 2004-08-09

Last Posted Date: 2013-04-12

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 110

Registration Number: NCT00005076

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer

Phase 2

Terminated

Conditions: Kidney Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: irinotecan hydrochloride

First Posted Date: 2004-08-05

Last Posted Date: 2018-07-16

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 9

Registration Number: NCT00089102

Locations: 🇺🇸
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: irinotecan hydrochloride

First Posted Date: 2004-08-05

Last Posted Date: 2018-07-12

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 16

Registration Number: NCT00089128

Locations: 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

First Posted Date: 2004-07-30

Last Posted Date: 2013-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00003055

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Irinotecan in Treating Patients With Esophageal or Stomach Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: irinotecan hydrochloride

First Posted Date: 2004-07-22

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT00003748

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Cancer Care Associates Medical Group, Torrance, California, United States
🇺🇸
UCLA Cancer Center - Santa Clarita, Valencia, California, United States

and more 22 locations

Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: amifostine trihydrate
Drug: irinotecan hydrochloride

First Posted Date: 2004-07-21

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 23

Registration Number: NCT00003225

Locations: 🇺🇸
Wilshire Oncology Medical Group, Inc., Rancho Cucamonga, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States